Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Cancer. 2018 Apr 15;124(8):1710-1721. doi: 10.1002/cncr.31237. Epub 2018 Jan 23.
Outcomes have improved significantly in multiple myeloma (MM), but racial disparities in health care access and survival exist. A comprehensive analysis exploring MM care and racial disparities is warranted.
Patients with MM from 1991 to 2010 in the Surveillance, Epidemiology, and End Results-Medicare database were evaluated for racial trends in clinical myeloma-defining events (MDEs), the receipt of treatment (drugs and stem cell transplantation; [SCT]), the cost of care, and overall survival (OS).
Among 35,842 patients, the frequency of all MDEs at diagnosis increased over time; whereas, in recent years (2006-2010), all MDEs with the exception of renal dialysis decreased. Blacks had highest rates for all MDEs except bone fractures, which were highest in whites. Over time, the proportion of patients who received any treatment, multiple agents, and SCT increased significantly, and the largest increase was observed in the receipt of immunomodulatory drugs and steroids. There was greater receipt of bortezomib and SCT among whites and blacks and higher receipt of immunomodulatory drugs among Hispanics and Asians (P < .001). Medicare claims were highest during first 6 months after MM diagnosis for blacks and at any time after MM diagnosis for Hispanics. Over time, Medicare claims increased most steadily for Hispanics (P < .001). Hypercalcemia, renal dysfunction, and bone fractures were associated with inferior OS. Blacks and Asians had superior OS compared with whites, but racial differences in OS became less pronounced during 2006 through 2010 (P = .182) compared with prior years (P < .01). Better OS was noted among patients who had higher median incomes.
The current results indicate that there have been significant changes in the management of patients with MM over time and provide an in-depth understanding of the factors that may help explain racial disparities. Cancer 2018;124:1710-21. © 2018 American Cancer Society.
多发性骨髓瘤(MM)的治疗效果已有显著改善,但在医疗保健的可及性和生存方面仍存在种族差异。因此,有必要进行一项全面的分析,探讨 MM 的治疗情况和种族差异。
评估了 1991 年至 2010 年间监测、流行病学和最终结果-医疗保险数据库中 MM 患者的临床多发性骨髓瘤定义事件(MDE)、治疗(药物和干细胞移植[SCT])、治疗费用和总生存率(OS)方面的种族趋势。
在 35842 例患者中,所有 MDE 的诊断频率随时间增加;然而,近年来(2006-2010 年),除了肾脏透析外,所有 MDE 都有所减少。黑人的所有 MDE 发生率最高,除了白人的骨折发生率最高。随着时间的推移,接受任何治疗、多种药物和 SCT 的患者比例显著增加,其中免疫调节剂和类固醇的接受率增加最大。白人接受硼替佐米和 SCT 的比例更高,西班牙裔和亚洲人接受免疫调节剂的比例更高(P<0.001)。黑人的医疗保险理赔在 MM 诊断后 6 个月内最高,而西班牙裔在 MM 诊断后任何时候都最高。随着时间的推移,西班牙裔的医疗保险理赔增长最为稳定(P<0.001)。高钙血症、肾功能障碍和骨折与较差的 OS 相关。与白人相比,黑人亚洲人的 OS 较好,但在 2006 年至 2010 年期间,与前几年相比(P<0.01),OS 的种族差异变得不那么明显(P=0.182)。中位收入较高的患者 OS 较好。
目前的结果表明,随着时间的推移,MM 患者的治疗管理发生了重大变化,并深入了解了可能有助于解释种族差异的因素。癌症 2018;124:1710-21。©2018 美国癌症协会。